Evidence map›Paper›PMID 33833234›Full record

ArticleNature communications2021

Exploiting pyocyanin to treat mitochondrial disease due to respiratory complex III dysfunction.

Roberta Peruzzo, Samantha Corrà, Roberto Costa, Michele Brischigliaro, Tatiana Varanita, Lucia Biasutto, Chiara Rampazzo, Daniele Ghezzi, Luigi Leanza, Mario Zoratti and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The two faces of pyocyanin - why and how to steer its production?World journal of microbiology & biotechnology · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Tackling Dysfunction of Mitochondrial Bioenergetics in the Brain.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Roberta PeruzzoDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0001-9209-9068
Samantha CorràDepartment of Biology, University of Padova, Padova, Italy.
Roberto CostaDepartment of Biology, University of Padova, Padova, Italy.
Michele BrischigliaroDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0003-1520-1342
Tatiana VaranitaDepartment of Biology, University of Padova, Padova, Italy.
Lucia BiasuttoCNR Institute of Neuroscience, Padova, Italy.
Chiara RampazzoDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0002-1092-2653
Daniele GhezziUnit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.ORCID 0000-0002-6564-3766
Luigi LeanzaDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0002-5919-7114
Mario ZorattiCNR Institute of Neuroscience, Padova, Italy.
Massimo ZevianiDepartment of Neurosciences, University of Padova, Padova, Italy.ORCID 0000-0002-9067-5508
Cristiano De PittàDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0001-8013-8162
Carlo ViscomiDepartment of Biomedical Sciences, University of Padova, Padova, Italy.ORCID 0000-0001-6050-0566
Rodolfo CostaDepartment of Biology, University of Padova, Padova, Italy.ORCID 0000-0002-2489-9116
Ildikò SzabòDepartment of Biology, University of Padova, Padova, Italy. ildiko.szabo@unipd.it.ORCID 0000-0002-3637-3947
University of Padua · ITUniversity of Milan · IT

Funding

Medical Research Council MC_UP_1002/1MRF_ MRF-155-0002-RG-ZEVIA
6 · The paper itself

Abstract

Mitochondrial diseases impair oxidative phosphorylation and ATP production, while effective treatment is still lacking. Defective complex III is associated with a highly variable clinical spectrum. We show that pyocyanin, a bacterial redox cycler, can replace the redox functions of complex III, acting as an electron shunt. Sub-μM pyocyanin was harmless, restored respiration and increased ATP production in fibroblasts from five patients harboring pathogenic mutations in TTC19, BCS1L or LYRM7, involved in assembly/stabilization of complex III. Pyocyanin normalized the mitochondrial membrane potential, and mildly increased ROS production and biogenesis. These in vitro effects were confirmed in both Drosophila

Indexed as

Adenosine TriphosphateAnimalsAnimals, Genetically ModifiedATPases Associated with Diverse Cellular ActivitiesCell LineDrosophila melanogasterElectron Transport Complex IIIHumansMembrane Potential, MitochondrialMembrane ProteinsMiceMitochondrial DiseasesMitochondrial ProteinsMolecular ChaperonesOxidation-ReductionPyocyanineAdenosine TriphosphateATPases Associated with Diverse Cellular ActivitiesBCS1L protein, humanElectron Transport Complex IIILYRM7 protein, humanMembrane ProteinsMitochondrial ProteinsMolecular ChaperonesPyocyanineReactive Oxygen SpeciesTTC19 protein, human

Identifiers

PMID33833234
PMCPMC8032734
OpenAlexW3149706068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.